The global proteinuria treatment market size is worth US$ 1.9 Billion in 2022. The market is projected to witness a robust CAGR of 8% over the forecast period to arrive at a market valuation of US$ 4.10 Billion by 2032.
The market growth of proteinuria treatment is primarily driven by the rising pervasiveness of chronic kidney disease, which is a major cause of proteinuria, thus boosting the demand for proteinuria treatment. For instance, in March 2021, as per the Centers for Disease Control and Prevention, approximately one in seven, representing the population of over 37 million people, of which 15% were adults, are assessed to have chronic kidney disease in the U.S. Furthermore, as per the similar source, chronic kidney disease was determined to be predominant in people aged 65 years or above in comparison to people aged between 45-64 or 18-44 years.
The growth of the proteinuria treatment market is being propelled forward by the rising clinical development of proteinuria treatment drugs and kidney treatment drugs. For instance, in June 2021, Novartis, a leading healthcare provider, unveiled their Phase II primary endpoint data exhibiting that investigational ‘iptacopan’ minimized protein content in urine (proteinuria), the main risk indicator associated with the development of kidney failure. Iptocan is the highest grade, targeted factor B inhibitor, which also demonstrated a stabilizing effect on the functionality of the kidney in patients suffering from IgA nephropathy.
The growth of the proteinuria treatment market is predicted to be fostered by the increasing mergers, acquisitions, and agreements by market players to further their growth. For instance, in January 2020, Chinook Therapeutics Inc., a firm specialized in biotechnology focused on the development of precision medicines to treat kidney diseases, declared a license agreement with a research-based biopharmaceutical company named AbbVie, for the exclusive rights to ‘atrasentan’ globally, which is an endothelin receptor antagonist. The ‘atrasentan’ is being developed with an aim to treat primary glomerular diseases that are characterized by proteinuria.
The aforementioned factors are predicted to contribute to proteinuria treatment market growth over the forecast period.
| Attributes | Details |
|---|---|
| Proteinuria Treatment Market Value (2022) | US$ 1.9 Billion |
| Proteinuria Treatment Market Forecast Value (2032) | US$ 4.1 Billion |
| Proteinuria Treatment Market CAGR (2022 to 2032) | 5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Region-wise, the global proteinuria treatment market is [n1] classified into regions, namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, the Middle East, and Africa. North America dominates the global market for proteinuria treatment due to the high prevalence rate of diabetes and hypertension among the North American population. [n2] The regional market is further supported by the introduction of new drug applications to treat proteinuria-related diseases like nephropathy.
In March 2021, Calliditas Therapeutics AB formally declared the proposal of a New Drug Application (NDA) to the U.S. FDA for Nefecon, which is a novel oral formulation that targets IgA1 down-regulation for the therapy of primary IgA Nephropathy (IgAN). In part A of the phase III study, Nefecon met its prime endpoint of dropping proteinuria as opposed to a placebo, along with stabilizing the estimated glomerular filtration rate, short for eGFR at nine months.
Moreover, technological advancements in diagnostic tests further accentuate the market growth in this region. Europe holds the second position in proteinuria treatment owing to its large geriatric population base (people above 65 years of age). In addition to this, the market might further be propelled owing to the recent drug approvals by FDA or other regulatory authorities to treat proteinuria-related diseases like lupus nephritis. Asia-pacific holds the third and fourth position in the global proteinuria treatment market due to a lack of sufficient healthcare facilities (diagnostic tests).
American Diabetic Association stated that people with high blood pressure and diabetes are at high risk for developing proteinuria. Thus, increase in diabetic and hypertensive patients worldwide are the main driving factors for the growth of proteinuria treatment market.
Kidney disease often has no early symptoms. Hence, lack of awareness among people about proteinuria is expected to restrain the growth of global proteinuria treatment market.
Principal Consultant
Proteinuria can be diagnosed by urine albumin to creatinine ratio (UACR) test, glomerular filtration rate (GFR) test, renal ultrasound scan, and kidney biopsy test. Since proteinuria is a symptom and not a disease itself, medical care focuses on treating the underlying condition, such as normalizing blood pressure in people with hypertension or controlling blood sugar levels in those with diabetes.
However, drugs are even prescribed for people with diabetes and high blood pressure.
Region wise, the global proteinuria treatment marketis classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America dominates the global market for proteinuria treatment due to high prevalence rate of diabetes and hypertension among North American population.
Moreover, technological advancements in diagnostic test further accentuates the market growth in this region. Europe holds the second position in proteinuria treatment owing to its large geriatric population base (people above 65 years of age). Asia-pacific holds the third and fourth position in the global proteinuria treatment market due to lack of sufficient healthcare facilities (diagnostic test).
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the key players contributing to the global proteinuria treatment market includes Eli Lilly And Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca Plc., Reddys Lab, and Novartis AG.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Proteinuria treatment market can be segmented on the basis of drug type, distribution channel and geography.
The market is likely to register a CAGR of 5% through 2032.
The market is currently valued at US$ 1.9 Bn in 2022.
The market is likely to grow to a valuation of US$ 4.1 Bn by 2032.
North America is likely to be a leading market during the forecast period.
Explore Healthcare Insights
View Reports
Proteinuria Treatment Market
